China Diabetes Market Report and Forecast 2024-2032

China Diabetes Market Outlook

The China diabetes market size reached a value of almost USD 4.73 billion in the year 2023. The market is further expected to grow at a CAGR of 9.5% between 2024 and 2032 to reach a value of almost USD 10.68 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The China diabetes market is driven by numerous healthcare reforms. Currently, the country represents one of the largest diabetic populations across the globe. China has about 11% of the global adult diabetic population (according to the International Diabetes Federation), due to the increase of more than nine-fold increase in cases within a generation. This can be attributed to the unhealthy eating patterns, hectic lifestyle, significant economic growth, and lack of physical activity, accelerating the population of overweight and obese people in the country.

Properties and Applications

Diabetes is referred to as a chronic disease that adversely impacts the body's ability to generate adequate insulin, break down the sugar present in food, or use insulin efficiently. It can lead to premature death or severe complications, such as amputation, stroke, and kidney and heart diseases. Diabetes is mainly categorized into three types, such as type 1, type 2, and gestational diabetes.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The China diabetes market is bifurcated on the basis of segment into:

• China Oral Antidiabetics Market
• China Insulin Market

Currently, insulin holds the majority of the total market share due to the increasing number of production facilities across China. The manufacturers produce and supply insulin pumps, along with other insulin delivery systems throughout the country.

The major regional markets for the product include Shanghai, Zhejiang, Guangdong, Jiangsu, and Beijing, among others.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

The China diabetes market is driven by the higher vulnerability of Chinese people to diabetes as compared to Europeans. The industry is further aided by the unawareness regarding health issues, considerable consumption of white rice, and poor healthcare infrastructure in the country, which represent some of the major significant factors driving the incidences of diabetes. Thus, the Chinese government is introducing several healthcare reforms, which is invigorating the diabetes industry growth. For instance, it is encouraging foreign investments and permitting multinational companies (MNCs) to extend their services within China. This has helped patients to diagnose diabetes at the early stage and manage it properly. Also, several drug manufacturers in China are focusing on expanding their budget for research and development (R&D) activities in the industry to develop innovative drugs. This trend, along with the highly developed pharmaceutical industry within China, is contributing to the industry growth in the country.

Competitive Landscape

The report gives a detailed analysis of the following key players in the China diabetes market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Abbott
• Medtronic
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report